GTPBP2
Basic information
Region (hg38): 6:43605316-43629264
Links
Phenotypes
GenCC
Source:
- Jaberi-Elahi syndrome (Definitive), mode of inheritance: AR
- Jaberi-Elahi syndrome (Strong), mode of inheritance: AR
- Jaberi-Elahi syndrome (Moderate), mode of inheritance: AR
- Jaberi-Elahi syndrome (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Jaberi-Elahi syndrome | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic | 26675814; 29449720 |
ClinVar
This is a list of variants' phenotypes submitted to
- Jaberi-Elahi syndrome (2 variants)
- not provided (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GTPBP2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 49 | 56 | ||||
missense | 44 | 47 | ||||
nonsense | 2 | |||||
start loss | 0 | |||||
frameshift | 4 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 3 | 4 | 7 | |||
non coding | 19 | 28 | ||||
Total | 3 | 3 | 46 | 70 | 16 |
Variants in GTPBP2
This is a list of pathogenic ClinVar variants found in the GTPBP2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
6-43605319-T-G | Xeroderma pigmentosum variant type | Uncertain significance (Jan 12, 2018) | ||
6-43605326-T-G | Xeroderma pigmentosum variant type | Conflicting classifications of pathogenicity (Jun 16, 2023) | ||
6-43605326-TTTTC-T | Likely benign (Feb 21, 2023) | |||
6-43605327-T-A | Likely benign (Nov 10, 2023) | |||
6-43605330-C-A | Likely benign (Jan 25, 2024) | |||
6-43605497-T-G | Benign (Jul 10, 2018) | |||
6-43605580-C-T | Likely benign (Jul 14, 2018) | |||
6-43610271-GC-G | Likely benign (Jul 05, 2018) | |||
6-43610541-T-C | Likely benign (Mar 13, 2023) | |||
6-43610541-T-G | Likely benign (Jan 03, 2024) | |||
6-43610544-C-A | Likely benign (Oct 28, 2023) | |||
6-43610548-C-T | Likely benign (Dec 13, 2022) | |||
6-43610550-A-G | Likely benign (Dec 05, 2023) | |||
6-43610556-T-TG | Xeroderma pigmentosum | Pathogenic (Feb 05, 2023) | ||
6-43610571-C-G | Likely benign (Jan 29, 2023) | |||
6-43610579-T-C | Inborn genetic diseases | Likely benign (May 08, 2023) | ||
6-43610589-T-C | Likely benign (Oct 29, 2023) | |||
6-43610590-C-T | Uncertain significance (Apr 29, 2019) | |||
6-43610592-T-C | Likely benign (Apr 11, 2023) | |||
6-43610596-C-T | Xeroderma pigmentosum variant type | Pathogenic (Aug 01, 2023) | ||
6-43610610-C-T | Likely benign (Feb 01, 2024) | |||
6-43610619-C-T | Likely benign (Apr 14, 2023) | |||
6-43610642-C-A | Xeroderma pigmentosum variant type • Inborn genetic diseases | Uncertain significance (May 23, 2023) | ||
6-43610644-C-T | Uncertain significance (Apr 12, 2022) | |||
6-43610660-A-G | Xeroderma pigmentosum | Uncertain significance (Sep 14, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GTPBP2 | protein_coding | protein_coding | ENST00000307126 | 12 | 23847 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.317 | 0.683 | 125732 | 0 | 16 | 125748 | 0.0000636 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.43 | 182 | 367 | 0.496 | 0.0000230 | 3869 |
Missense in Polyphen | 49 | 152.8 | 0.32068 | 1598 | ||
Synonymous | -0.0964 | 151 | 150 | 1.01 | 0.00000877 | 1290 |
Loss of Function | 3.93 | 7 | 30.4 | 0.231 | 0.00000200 | 304 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000615 | 0.0000615 |
Ashkenazi Jewish | 0.000100 | 0.0000992 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000925 | 0.0000924 |
European (Non-Finnish) | 0.0000615 | 0.0000615 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.000163 | 0.000163 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Pathway
- Platelet degranulation ;Response to elevated platelet cytosolic Ca2+;Platelet activation, signaling and aggregation;Hemostasis
(Consensus)
Recessive Scores
- pRec
- 0.135
Intolerance Scores
- loftool
- 0.516
- rvis_EVS
- -0.43
- rvis_percentile_EVS
- 25.37
Haploinsufficiency Scores
- pHI
- 0.358
- hipred
- Y
- hipred_score
- 0.685
- ghis
- 0.588
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.860
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gtpbp2
- Phenotype
- cellular phenotype; homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); immune system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- platelet degranulation;translational elongation;biological_process
- Cellular component
- extracellular region;platelet alpha granule lumen;intracellular membrane-bounded organelle
- Molecular function
- translation elongation factor activity;GTPase activity;protein binding;GTP binding